Comparative Pharmacology
Head-to-head clinical analysis: CENTRAX versus MENRIUM 10 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CENTRAX versus MENRIUM 10 4.
CENTRAX vs MENRIUM 10-4
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion influx and hyperpolarization of neurons, resulting in anxiolytic, sedative, and muscle relaxant effects.
Mennium 10-4 is a combination of chlordiazepoxide, a benzodiazepine that enhances GABA-A receptor activity, and clidinium, an antimuscarinic that blocks muscarinic acetylcholine receptors.
10-30 mg orally, 3-4 times daily.
Adults: 1 tablet (chlordiazepoxide 10 mg / clidinium 4 mg) orally 3 to 4 times daily before meals and at bedtime. Max: 4 tablets per day.
None Documented
None Documented
60-120 hours (mean 100 hours); long half-life leads to accumulation upon multiple dosing and prolonged sedation.
Chlordiazepoxide: 5-30 h (mean 20 h); clidinium: 10-20 h. Steady-state reached in 5-7 days.
Renal (primarily as glucuronide conjugates; <1% unchanged); biliary/fecal: minimal (less than 5%).
Renal (60% as unchanged chlordiazepoxide, 15% as conjugated metabolites; 5% biliary/fecal as metabolites)
Category C
Category C
Benzodiazepine
Benzodiazepine/Estrogen Combination